Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease

BACKGROUND: Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommende...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Hippokratia
Huvudupphovsmän: Vega, A, Abad, S, Verdalles, U, Aragoncillo, I, Velazquez, K, Quiroga, B, Escudero, V, López-Gómez, JM
Materialtyp: Artigo
Språk:Inglês
Publicerad: SOCIETY OF "FRIENDS OF HIPPOKRATIA JOURNAL" 2014
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453804/
https://ncbi.nlm.nih.gov/pubmed/26052197
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk